Ferreira, Fabio FurlanAntoni, Selma Gutierrez [UNESP]Pires Rosa, Paulo CesarPaiva-Santos, Carlos de Oliveira [UNESP]2014-05-202014-05-202010-04-01Journal of Pharmaceutical Sciences. Hoboken: John Wiley & Sons Inc, v. 99, n. 4, p. 1734-1744, 2010.0022-3549http://hdl.handle.net/11449/25544The crystal structure determination of mebendazole form A, an anthelmintic drug, was performed for the first time by applying the DASH software program to synchrotron X-ray powder diffraction data, and supported by a satisfying Rietveld fit. This polymorph of mebendazole crystallizes in a triclinic (P (1) over bar) space group, with unit-cell parameters a = 5.5044(2)angstrom, b = 11.2872(2)angstrom, c = 12.5276(5)angstrom, a= 66.694(2)degrees, beta = 82.959(2)degrees, gamma = 78.443(2)degrees, V = 699.52(5)angstrom(3), Z = 2, M = 295.293 g mol(-1), rho(calc) = 1.4021 g cm(-3), and rho(meas) = 1.3935(66) g cm(-3), which were obtained by means of the unit-cell formula weight and a picnometric measurement, respectively. The goodness-of-fit and R-factors were, respectively: chi(2) = 1.746, R(F)(2) = 1.69%, R(wp) = 5.72%, and R(p) = 4.37%. A weak nonclassical hydrogen bond involving the atoms N(3)-H(23)center dot center dot center dot O(11) may be responsible for the greater stability of the polymorphic form A of mebendazole due to the strongest electronegativity of nitrogen. (C) 2009 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 99:1734-1744, 20101734-1744engX-ray powder diffractometrycrystal structurepolymorphismcrystallographyab initio calculationsquantitative phase analysissynchrotronmebendazolepolymorph Aanthelmintic drugArtigo10.1002/jps.21902WOS:000276226300008Acesso restrito